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Abstract: Care for diabetic wounds remains a significant clinical problem. The present 
study was aimed at investigating the effect of skin gelatin from Chum Salmon on defective 
wound repair in the skin of diabetic rats. Full-thickness excisional skin wounds were made 
in 48 rats, of which 32 were diabetes. The diabetic rats were orally treated daily for 14 days 
with skin gelatin from Chum Salmon (2 g/kg) or its vehicle. Sixteen non-diabetic control 
rats received the same amount of water as vehicle-treated non-diabetic rats. Rats  were 
killed to assess the rate of wound closure, microvessel density (MVD), vascular endothelial 
growth  factor  (VEGF),  hydroxyproline  (HP)  contents  in  wound  tissues  and  nitrate  in 
plasma and wound tissue at 7 and 14 days after wounding. Skin gelatin-treated diabetic rats 
showed a better wound closure, increased MVD, VEGF, hyproxyproline and NO contents 
and a reduced extent of inflammatory response. All parameters were significant (P < 0.05) 
in comparison to vehicle-treated diabetic group. In light of our finding that skin gelatin of 
Chum  Salmon  promotes  skin  wound  repair  in  diabetic  rats,  we  propose  that  oral 
administration of Chum Salmon skin gelatin might be a beneficial method for treating 
wound disorders associated with diabetes. 
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1. Introduction  
Chronic  wound  healing  is  a  troublesome  and  common  complication  of  diabetes,  resulting  in 
significant clinical morbidity, such as nonhealing ulcers, infection, gangrene and amputation [1,2]. 
In recent years, treatment of diabetic wounds has intensified, but the amputation rate remains high and 
is associated with increased morbidity and mortality [3]. Thus, care for diabetic wounds remains a 
significant clinical problem and the development of therapies that improve wound healing in diabetic 
patients  is  of  critical  importance.  However,  due  to  toxicity  or  intolerance  reactions  in  individual 
patients, therapeutic responses are limited in many diabetic patients despite the availability of new 
agents.  Thus,  compounds  that  provide  greater  symptomatic  relief  with  less  overall  toxicity  and 
minimal risks are preferred.  
For the same reason, there is growing interest in gelatin as a therapeutic agent of potential utility in 
the treatment of wound healing for a high level of safety and overall lack of toxicity. Nowadays, over 
250,000 metric tons of gelatin are produced worldwide every year, of which 60% is consumed by 
humans as a variety of products [4]. The authors also suggested that the unique amino acid and peptide 
profile of gelatin may be responsible for clinical observations supporting wound therapeutic efficacy. 
Since marine organisms comprise approximately one-half of the total global biodiversity, the sea is an 
enormous resource for novel compounds. Moreover, with recent advances in the high-tech instruments 
for isolation and characterization of marine natural products, there has been a growing interest in the 
importance of marine life as a source of new biologically active substances. Marine fish skin can serve 
as an additional source of proteins, especially gelatin. The uniqueness of gelatin from fish skin lies in 
its amino acid content. Although all gelatins are composed of the same 20 amino acids, there can be 
variation  in  the  amount  of  amino  acids,  proline  and  hydroxyproline.  Gelatin  is  effective  in  the 
treatment of wound healing based on clinical and animal studies [5–7]. Topical skin gelatin treatment 
has been proven to be effective for accelerating wound healing as part of photographic film [8,9]. 
However,  it  is  not  known  whether  oral  administration  of  skin  gelatin  from  Chum  Salmon 
(Oncorhynchus  keta)  has  enhancing  effects  on  cutaneous  wound  healing  in  diabetic  patients. 
Therefore, the purpose of the present  study was to investigate the possible beneficial role of skin 
gelatin derived from Chum Salmon in an experiment model of type 1 diabetes-related wound healing 
disorders. These experiments could help to clarify the complex molecular interplay between wound 
healing and angiogenesis in diabetes and the possibility to prevent the cellular and molecular liabilities 
that hamper proper reparative angiogenesis. 
2. Results 
2.1. Animal Characteristics 
The body weight and blood glucose levels of all animals at the time of wounding and at termination 
are  shown  in  Table  1.  Diabetic  rats  of  both  the  vehicle-  and  skin  gelatin-treated  groups  weighed 
significantly less at the end of the experiment compared to the day of wounding. Despite reduction of 
body weight, no difference was observed between the vehicle- and skin gelatin-treated groups over the 
process  of  the  experiment.  Blood  glucose  levels  in  diabetic  rats  used  in  the  present  study  were Mar. Drugs 2011, 9  
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consistently higher than 250 mg/dL and these levels were not changed by administration of skin gelatin 
from Chum Salmon.  
Table 1. Effect of oral skin gelatin treatment on body weight and blood glucose levels in 
the three experimental groups. 
 
Vehicle-treated  
non-diabetic (n = 8) 
Vehicle-treated 
diabetic (n = 8) 
Skin gelatin-treated 
diabetic (n = 8) 
P-value 
(between groups 
after treatment)  Day 0  Day 14  Day 0  Day 14  Day 0  Day 14 
Body weight (g)  263 ±  11  297 ±  13  248 ±  10  232 ±  16  250 ±  12  234 ±  14  <0.05 
Blood glucose 
levels (mg/dL) 
115 ±  6.3  119 ±  5.8  398 ±  26  384 ±  23  402 ±  27  389 ±  28  <0.05 
Values are presented as mean ±  SD. Statistical significance is set at P < 0.05. 
2.2. Effect of Chum Salmon Skin Gelatin Treatment on Wound Closure 
Firstly, the difference in wound healing between non-diabetic rats and diabetic rats was measured. 
As illustrated in Figure 1, the wound area of non-diabetic rats contracted almost to 17% of the original 
size by day 14 post-wounding, whereas diabetic rats showed significantly delayed wound healing: the 
wound area contracted to 42% of the original size by day 14. Next, the effect of skin gelatin treatment 
on  wound  closure  in  diabetic  rats  was  investigated.  The  wound  area  seemed  smaller  in  the  skin  
gelatin-treated  diabetic  rats  than  in  the  vehicle-treated  diabetic  rats  by  day  7  and  14.  In order  to 
confirm this observation, the wound area was measured. The percentage of original wound area in the 
skin gelatin-treated diabetic rats was 16% smaller on day 7 and 35% smaller on day 14 compared to 
the vehicle-treated diabetic group.  
Figure 1. Effect of oral skin gelatin administration at the time of wounding on cutaneous 
wound  closure  rate  in  diabetic  rats.  (A)  Representative  photos  of  wounds  in  the  
non-diabetic  and  diabetic  rats  treated  with  either  vehicle  or  skin  gelatin  at  day  14  
(a, vehicle-treated non-diabetic rats; b, vehicle-treated diabetic rats; c, skin gelatin-treated 
diabetic rats); (B) Group data of wound closure rate expressed as a percentage (%) of the 
initial wound size. The surface areas of the healing wounds were measured every 2 days 
and compared by one-way analysis of variance. * P < 0.05, ** P < 0.01—significance of 
the difference between the mean wound surface area of the vehicle-treated diabetic group 
and that of the vehicle-treated non-diabetic group. 
# P < 0.05, 
## P < 0.01—significance of 
the difference between the mean wound surface area of the skin gelatin-treated diabetic 
group and that of vehicle-treated diabetic group. 
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Figure 1. Cont. 
 
2.3. Effect of Skin Gelatin on Wound MPO Activity 
Myeloperoxidase (MPO) activity in wounds from non-diabetic and diabetic animals was measured 
as an indicator of wound inflammatory activity. MPO activity was found to increase to an average of 
three and four-folds in vehicle-treated diabetic wounds by day 7 and 14 post-wounding compared with  
vehicle-treated  non-diabetic  animals,  respectively.  In  vehicle-treated  non-diabetic  animals,  wound 
MPO activity decreased with healing time. In the vehicle-treated diabetic wounds, the MPO activity 
remained  significantly  elevated  at  day  14.  Skin  gelatin  treatment  of  wounds  in  the  diabetic  rats 
prevented this increase (Figure 2). 
Figure 2. Effect of oral administration of skin gelatin on wound myeloperoxidase (MPO) 
activity in non-diabetic and diabetic rats at days 7 and 14. Results are mean ±  SD, analyzed 
by ANOVA. * <0.05 different from same-day between two group. ** <0.01 different from 
same-day between two group. 
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2.4. Histological Examinations 
The histological examinations including the degree of fibroblast infiltration, collagen regeneration, 
vascularization  and  epithelialization  in  the  wound  area  are  shown  in  Table  2.  Compared  with  
vehicle-treated  diabetic  rats,  a  significant  increase  in  the  number  of  infiltrated  fibroblasts  in  the 
subcutaneous  tissue  in  the  skin  gelatin-treated  diabetic  group  was  seen  by  day  7  post-wounding  
(P < 0.05). Vascularization was significantly higher in the skin gelatin-treated diabetic rats than in the  
vehicle-treated diabetic group at 7 days (P < 0.05). Furthermore, significantly denser distribution as 
well as abundant collagen regeneration was observed in the skin gelatin-treated diabetic group at 7 and 
14 days post-wounding (P < 0.05). Moreover, epithelialization was significantly greater in the skin 
gelatin-treated diabetic group than in the vehicle-treated diabetic group on day 14 (P < 0.05). 
Table 2. Histological scorings. 
  Fibroblasts  Vascularization  Collagen  Epithelialization 
Day 7         
Vehicle-treated non-diabetic  1.4 ±  0.2  1.2 ±  0.1  1.7 ±  0.1  1.8 ±  0.2 
Vehicle-treated diabetic  1.3 ±  0.2  1.2 ±  0.2  0.9 ±  0.2 **  1.2 ±  0.3 ** 
Skin gelatin-treated diabetic  1.8 ±  0.2 
#  1.4 ±  0.1 
#  1.3 ±  0.1 
#  1.5 ±  0.2 
# 
Day 14         
Vehicle-treated non-diabetic  1.8 ±  0.2  1.9 ±  0.1  1.9 ±  0.1  2.6 ±  0.3 
Vehicle-treated diabetic  1.7 ±  0.2  1.6 ±  0.2 *  1.2 ±  0.1 **  1.8 ±  0.2 ** 
Skin gelatin-treated diabetic  2.3 ±  0.2 
#  2.3 ±  0.2 
#  1.5 ±  0.2 
#  2.2 ±  0.2 
# 
Note: Histological scorings were performed among the treatment groups. Data is expressed as mean 
±  SD. * P < 0.05, ** P < 0.01—significance of the difference between the vehicle-treated diabetic 
group  and  the  vehicle-treated  non-diabetic  group. 
#  P  <  0.05—significance  of  the  difference 
between the skin gelatin-treated diabetic group and the vehicle-treated diabetic group. 
2.5. Collagen Accumulation 
Collagen deposition is an important event in the development of granulation tissue. Compared with 
the  vehicle-treated  diabetic  group,  the  wound  revealed  a  marked  and  robust  increase  in  the 
organization  of  collagen  fibers  bridging  the  gaps  in  the  skin  gelatin-treated  diabetic  rats.  Thus, 
collagen fibers were more organized and dense in the skin gelatin-treated diabetic group than in the 
vehicle-treated group (Figure 3A). To confirm these histological observations, hydroxyproline (HP) 
contents were measured in the lesions by 7 and 14 days after wounding. The results showed that 
hydroxyproline contents in the skin gelatin-treated diabetic group were higher than in the vehicle-treated 
diabetic group and significant differences were observed by 7 and 14 days post-wounding (P < 0.01) 
(Figure 3B). 
2.6. Evaluation of Immunostaining for VEGF 
The  VEGF  immunoreactivity  of  wound  sections  was  examined  in  the  skin  gelatin-  and  
vehicle-treated groups at 14 days post-wounding and the numbers of fibroblasts expressing VEGF 
were counted. As shown in Figure 4, VEGF immunolabeling was striking in the skin gelatin-treated Mar. Drugs 2011, 9  
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diabetic rats, whereas it was faint in the vehicle-treated diabetic group. The numbers of migrated 
fibroblasts expressing VEGF in the skin gelatin-treated diabetic group were significantly higher than in 
the vehicle-treated diabetic group at 14 days post-wounding. 
Figure  3.  Collagen  accumulation  in  wound  areas  of  vehicle-  and  skin  gelatin-treated  
non-diabetic  or  diabetic  rats.  (A)  Representative  high  power  view  light  micrographs 
(Masson’s  trichirome  staining)  at  day  14  (a,  vehicle-treated  non-diabetic  rats;  
b, vehicle-treated diabetic rats; c, skin gelatin-treated diabetic rats); (B) Hydroxyproline 
levels in wound areas of the all treatment groups at day 7 and 14. Data are expressed as 
mean ±  SD. * <0.05 different from same-day between two groups. ** <0.01 different from 
same-day between two groups. 
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Figure  4.  Expression  of  VEGF  in  wound  tissue  at  day  14  after  wounding  in  
(a)  vehicle-treated  non-diabetic  rats;  (b)  vehicle-treated  diabetic  rats  and  (c)  skin  
gelatin-treated diabetic rats. Statistical analysis showed that the extent immunoreactivity of 
VEGF  in  the  wound  areas  skin  gelatin-treated  diabetic  rats  is  greater  than  that  of  
the vehicle-treated diabetic group. * P < 0.05—significance of the difference between the 
mean  VEGF  in  the  wound  area  of  skin  gelatin-treated  diabetic  rats  and  that  of  
vehicle-treated diabetic rats (magnification 200× ; V, vessel). 
 
2.7. Effect of Skin Gelatin on MVD 
After 14 days, the microvessel density (MVD) of the vehicle-treated wounds of diabetic rats was 
significantly lower than that of the vehicle-treated wounds of non-diabetic rats. When tissues from the 
vehicle-treated  wounds  of  diabetic  rats  were  examined  histologically,  there  were  avascular  areas, 
ectasic  vessels  with  edema  and  perivascular  hemorrhage,  and  a  marked  reduction  in  capillary 
ramification.  The MVDs in skin gelatin-treated  wounds  were significantly higher than that in the 
vehicle-treated wounds of diabetic rats (Figure 5).  Mar. Drugs 2011, 9  
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Figure 5. Oral skin gelatin treatment increases microvessel density (MVD) by 14 days after 
wounding by CD31
+ cells counting. Statistic analysis showed that microvessel density in the 
wound  areas  of  skin  gelatin-treated  diabetic  rats  is  greater  than  that  of  vehicle-treated 
diabetic group. Each bar represents the mean MVD ±  SD of the pooled data from each 
treatment group. * P < 0.05—significance of the difference between the mean MVD in the 
wound area of skin gelatin-treated diabetic rats and that of vehicle-treated diabetic rats.  
 
2.8. Measurement of Nitrite Levels 
Nitrite dosage was used as an index of NO synthesis, because nitrite is a stable molecule and 
accounts for more than 90% of total measurable nitrite and nitrate. Fourteen days after wounding, the 
nitrite levels were respectively 5-fold and 1.7-fold greater in the skin gelatin-treated group than in the 
control group in both the wound and plasma (Figure 6).  
Figure 6. Nitrite levels in wounds and plasma of the non-diabetic and diabetic rats treated 
with  either  vehicle  or  skin  gelatin  at  day  14  after  wounding.  Data  are  expressed  as  
mean ±  SD. * P < 0.05 different from same-day between two groups. ** P < 0.01 different 
from same-day between two groups. 
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3. Discussion 
The present study presented that oral administration of skin gelatin from Chum Salmon accelerates 
cutaneous wound healing in the skin of diabetic rats.  
The inability of wounds to heal in diabetes mellitus patients is associated with an abnormality in 
one or more phases of the healing process. In our study, we observed that defective wound repair in 
diabetic rats is associated with reduced wound vascularization and collagen synthesis, and with an 
increased extent of inflammatory cells in wound tissues. 
In acute wound healing, the inflammatory response should occur rapidly and sustain for 3 days to 
permit  the  development  of  subsequent  phases  of  wound  healing  [10–12].  This  requires  that 
inflammatory cells (such as neutrophils and macrophages) migrate to the wound area and phagocytize 
necrotic tissue and microorganisms. However, the inflammatory response in chronic wound healing, 
such  as  diabetes,  will  last  for  extended  periods  and  affect  wound  regeneration.  To  evaluate  the 
inflammatory  infiltrate,  MPO  activity,  a  better  indicative  of  the  inflammatory  activity  in  the 
granulation tissue, was measured 14 days after wounding. The inflammatory response was higher in 
the  diabetic  group  until  14  days  after  wounding  in  the  present  study.  Skin  gelatin  administration 
significantly reduced the inflammatory response and increased the quantity of fibroblast cells in the 
wound area of diabetic rats when compared to vehicle-treated diabetic group. The positive effect of skin 
gelatin on the inflammatory response of diabetic lesions may be explained by skin gelatin-stimulated 
NO  synthesis,  which  was  consistent  with  previous  work  [13,14]:  NO  may  directly  stimulate  the 
production  of  cytokines  of  inflammatory  cells,  consequently  accelerating  the  development  of  the 
subsequent phases of wound healing.  
Wound  closure  involves  a  complex  and  superbly  orchestrated  interaction  of  cells,  extracellular 
matrix, and cytokines. The increased rate of wound closure in skin gelatin-treated wounds might be 
attributed  to  increased  proliferation  and  transformation  of  fibroblast  cells  into  myofibroblasts. 
Histological findings also showed enhanced proliferation of fibroblasts and re-epithelialization in skin 
gelatin-treated wound tissues of diabetic rats. The early re-epithelialization and faster wound closure in 
skin gelatin-treated wounds might also be associated with increased keratinocytes proliferation, and 
their migration to the wound surface [15,16].  
The fibroblasts are responsible for the synthesis, deposition, and remodeling of the extracellular 
matrix.  After  migrating  into  wounds,  fibroblasts  initiate  the  synthesis  of  the  extracellular  matrix. 
Collagen is a major protein of the extracellular matrix and is the component that ultimately contributes 
to wound strength [10]. The enhanced level of hydroxyproline in skin gelatin-treated diabetic rats 
probably provides the strength to the regenerated tissue.  
Angiogenesis during wound repair serves the dual function of providing the nutrients required by 
supply  essential  nutrients  and  oxygen  to  the  wound  site,  and  promoting  granulation  tissue 
formation [11,17,18].  In  the  present  study,  skin  gelatin  was  found  to  increase  angiogenesis  as 
evidenced by MVD. Histological evaluation also revealed increased blood vessel formation in the 
granulation  tissue  of  skin  gelatin-treated  diabetic  rats.  Enhanced  expression  of  VEGF  as  revealed 
through immunohistochemistry in skin gelatin-treated diabetic rats as compared with vehicle-treated 
diabetic group might be responsible for this activity. In fact, it is well-known that vascular endothelial 
growth factor (VEGF) produced by fibroblasts is one of the most potent angiogenic cytokines [19,20]. Mar. Drugs 2011, 9  
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VEGF  appears  to  be  a  key  factor  in  pathological  situations  such  as  tissue  repair,  which  involves 
neovascularization  and  increased  vascular  permeability.  VEGF  improves  angiogenesis  during  the 
process of wound healing by stimulating the migration of endothelial cells through the extracellular 
matrix [21]. In agreement with our present finding, Galiano et al. [22] demonstrated that VEGF local 
therapy in db/db mice enhanced neovascularization at the wound site through a stimulation of local 
angiogenesis, thus suggesting that VEGF or agents stimulating its production may be exploited to 
promote tissue repair in a wide variety of acute and chronic injuries, particularly in conditions such as 
diabetes or aging [23]. However, it seems that VEGF staining is much lower in control non-diabetic 
rats than in vehicle treated diabetic rats. It could be interesting to compare at an earlier stage, for 
example day 7, since at day 14 the granulation tissue of non diabetic wounds is more mature and the 
signal could be lower.  
In the present study, skin gelatin administration enhanced blood vessel density in excisional lesions 
of diabetic rats when compared to the vehicle-treated diabetic group. The beneficial effect of skin 
gelatin on angiogenesis in diabetic lesions may be explained by the increased NO synthesis. It has been 
shown that NO increases VEGF expression, which is the most potent angiogenic factor during wound 
healing [14], thereby, stimulating the formation of new blood vessels [24]. Thus, we suggest that skin 
gelatin treatment may result in enhanced angiogenesis through its stimulatory effects on NO synthesis 
leading to improved formation of granulation tissue. 
In addition, there is abundant evidence suggesting that oxygen free radicals play an important role 
in diabetic wounds. These molecules cause failure of diabetic wound healing; therefore, antioxidants 
partly improve the healing in diabetic skin wounds [25]. It was also found that in some injury cases 
ointment contains superoxide dismutase (SOD), which stimulates wound healing. Our previous study 
and  other studies have  demonstrated  that  marine  fish skin gelatin  has  potent antioxidant and  free 
radical scavenging effect [26–28]. Hence we speculated that skin gelatin from Chum Salmon enhanced 
induction of antioxidant levels at an initial stage of healing, which may be an important contributory 
factor in the healing property.  
4. Methods 
4.1. Preparation of Skin Gelatin 
Gelatin was derived from the skin of wild-caught Chum Salmon (O. keta) (average body weight, 
1.47 kg) and donated by CF Haishi Biotechnology Ltd. Co. (Beijing, China). The procedure of skin 
gelatin preparation and identification is according to the method described previously [29,30]. In brief, 
after descaling, Chum Salmon skin was washed with running tap water for 1 h. It was then soaked in 
0.4 (w/v) NaOH and HCl aqueous solution for 4 h at room temperature, respectively. The skin was 
washed again with running tap water until pH was neutral. Finally, the skin was extracted with distilled 
water for 1.5 h at 70 °C . The extract was filtered through two layers of cheese cloth and evaporated at 
70 °C  to remove 70% of water. The filtrate was dried in a hot-air oven at 50 °C  for 18 h. The resulting 
gelatin was stored in a desiccator for further use. Mar. Drugs 2011, 9  
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4.2. Formation of Diabetic Rats 
All experimental procedures in this study were in accordance with the guidelines prepared by the 
Animal Care and Committee of Peking University Animal Center. Forty-eight male Sprague-Dawley 
rats  weighting  250–300  g  were  housed  individually  in  rooms  maintained  under  controlled 
environmental conditions (12-h light/dark cycle, temperature approximately 25 °C ). The rats were 
acclimated for 1 week before the study and had free access to standard laboratory chow and water  
ad libitum.  Diabetes was induced  by  a  single  45 mg/kg intraperitoneal injection  of streptozotocin 
(Sigma, St Louis, MO, USA) in saline-sodium citrate buffer. Blood glucose levels were measured 
using  a  rapid  glucometer.  Ten  days  after  streptozotocin  injection,  thirty-two  animals  with  blood 
glucose levels above 250 mg/dL were defined as diabetic and used in the study. Sixteen healthy rats 
were used as the vehicle-treated non-diabetic control group. 
4.3. Full-Thickness Skin Wound Preparation 
Ten  days  after  streptozotocin  administration,  all  rats  were  anesthetized  with  an  intraperitoneal 
injection of sodium pentobarbital (45 mg/kg body weight). The dorsal region was shaved with an 
electric clipper and the surgical area was disinfected with 70% alcohol. A sterile template of 2.0 cm in 
diameter  was  placed  on  each  side  of  the  mid-back  and  a  full-thickness  wound  to  deep  fascia 
corresponding to the template was made by excising the skin. The wounding day was considered as 
day  zero. Food  consumption, body  weight  and blood  glucose levels were recorded on the day of 
wounding, and thereafter weekly until euthanasia. 
The 32 diabetic rats were then divided randomly into 2 groups: skin gelatin-treated diabetic group 
(n  =  16),  which  received  skin  gelatin  from  Chum  Salmon,  2  g/kg· bw,  dissolved  in  water;  and  
vehicle-treated diabetic group (n = 16), which received water (in the same amount as the experimental 
group). The non-diabetic control rats (n = 16) received the same amount of water (vehicle-treated  
non-diabetic  group).  Oral  administration  of  skin  gelatin  began  on  the  wounding  day  and  was 
maintained daily until to sacrifice.  
4.4. Wound Closure Measurement 
The edge of migration epithelium was easily discernible from the moist granulation tissue and the 
presence of the epithelial border was the edge of the healing wound. The edge of the wound was traced 
onto  transparent  paper  every  2  days  and  the  wound  area  was  determined  by  planimetry  using 
Imagemeasure.  The  trace  taken  immediately  after  wounding  was  used  as  the  original  area  
(day 0 area).  
4.5. Histological Analysis 
After the final wound tracing on either day 7 or day 14, eight rats of each group were given a lethal 
ethylether inhalation, and the entire wound, including a 5 mm margin of unwounded skin, was excised 
down to the fascia. The wound was divided in half through the least healed portion. One-half of the 
wound was stored in the liquid nitrogen for future molecular studies, the other half was fixed in 10% 
neutral-buffered  formalin  for  at  least  24  h,  followed  by  processing  for  conventional  paraffin Mar. Drugs 2011, 9  
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embedding. 5 μm-thick sections were mounted on glass slides, dewaxed, rehydrated to distilled water, 
and stained with hematoxylin and eosin (H&E) or Masson’s Trichrome. As part of the histological 
evaluation, all slides were examined by two pathologists, without knowledge of the previous treatment, 
under a microscope from 20×  to 100×  magnification. Sections were semi-qualitatively assessed under 
the  light  microscope  and  observed  in  respect  of  fibroblast  proliferation,  collagen  formation, 
angiogenesis and epithelialization using a 4-point scale as follows: (0: none; 0.5: few; 1: moderate;  
2: many and 3: considerable). 
4.6. Immunohistochemistry 
Paraffin-embedded tissues were sectioned (5 μm), and antigen retrieval was performed using in 
10 mM sodium citrate buffer. Endogenous peroxidase activity was blocked by treating sections with 
0.3%  hydrogen  peroxide  in  methanol  for  15  min.  Tissues  were  treated  with  polyclonal  rabbit  
anti-VEGF and anti-CD31 antibody (Santa Cruz Biotechnology, Inc., USA; dilution 1:300) overnight 
at  4  ° C.  Specific  labeling  was  detected  with  a  peroxidase-conjugated  goat  anti-rabbit  IgG  and  
avidin-biotin  peroxidase  complex.  Slides  were  then  mounted  with  coverslips  and  analyzed  by 
two blinded pathologists. Assessment of immunoreactive cell density in the tissue was performed and 
graded semi-quantitatively as absent (0), few (1), moderate (2) or numerous (3). 
4.7. Assess of MVD 
Microvessel  density  (MVD)  in  the  wound  granulation  tissues  was  assessed  as  a  parameter  of 
wound-induced  angiogenesis  in  a  blind  manner  according  to  the  established  methods  described 
previously [31]. The expression levels of CD31 antigen can be used to assess MVD in healing wounds. 
MVD was determined in five regions of interest in each specimen in which the CD31 antibody signal 
was  the  moist  intense.  The  number  of  blood  vessels  was  counted  under  a  light  microscope  by 
two investigators who were blinded to the treatment of the rats. Microvessel density was expressed in 
terms of microvessel number per observed area (vessel number/mm
2). 
4.8. MPO Activity Assay 
To estimate the number of neutrophils in the wounded area, myeloperoxidase (MPO) activity in 
wound lysate was assayed according to Stark and collaborators with minor modifications [32]. An 
aliquot of wound lysate was mixed in phosphate buffer (80 mM) containing 0.5% hexadecyltrimethyl 
ammonium bromide at pH 5.5. The mixture was centrifuged at 12,000 rpm for 15 min to extract the 
MPO. Subsequently, the supernatant was mixed with 3,3′,5,5′-tetramethylbenzidine dihydrochloride 
(1.9 mg/mL) and hydrogen peroxide. Thereafter, the mixture was incubated at 37 ° C for 15 min and 
then  mixed  with  acetate  buffer  pH  3.0.  The  developed  color  was  read  spectrophotometrically  at 
630 nm.  MPO  concentrations  in  the sample  were  determined  from  a  standard  curve  generated  by 
different concentrations of MPO from human leukocytes. Data are expressed as mU MPO per mg 
total protein. Mar. Drugs 2011, 9  
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4.9. Determination of Nitrite Concentration 
Levels of nitrite in wound lysates and plasma were determined by a spectrophotometric method 
based on the Griess reaction. An aliquot of each sample (100 μg) was mixed and incubated with 
100 μL  of  Griess  reagent  at  room  temperature  for  10  min.  Thereafter,  the  developed  color  was 
spectrophotometrically read at 557 nm. Nitrite concentrations in the samples were determined from a 
standard curve generated by different concentrations of sodium nitrite. Data are expressed as μmol 
nitrite per μg total protein. 
4.10. Determination of the Hydroxyproline Content in the Wounds 
Full  thickness  skin  samples  taken  from  the  excision  were  weighed  and  kept  at  −20  °C   in 
physiological saline. To eliminate water, a 100 mg sample of excision wound tissue from each dead rat 
were kept at 60 °C  for 72 h in a drying oven and were weighed again. Dry and defatted tissue was 
hydrolyzed  in  6  M  HCl  for  18  h  at  110  °C .  Hydrolysate  was  then  diluted  with  distilled  water, 
neutralized with 6 M NaOH and centrifuged at 3000 rpm for 15 min. Hydroxyproline levels were 
measured in this hydrolysate as previously described [15]. The difference between wet and dry weights 
was taken as water ratio. 
4.11. Statistical Analysis 
Data for each study parameter from the skin gelatin- and vehicle-treated wound tissues for each 
group were presented as mean ±  standard deviation. Data from each group were statistically analyzed 
by one-way analysis of variance, except the data obtained from the semi-quantitative analysis using 
Kruskal-Wallis test. Differences were considered statistically significant when P < 0.05. 
5. Conclusions 
In conclusion, oral skin gelatin administration improves cutaneous wound healing of hyperglycemic 
diabetic rats by reducing inflammatory response, improving wound contraction, collagen deposition 
and  angiogenesis,  and  stimulating  NO  synthesis.  Taken  together,  all  evidence  above  leads  us  to 
propose that oral administration of skin gelatin from Chum Salmon might be a beneficial method for 
treating wound disorders associated with diabetes.  
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